Literature DB >> 25163639

A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics.

Sevilay Topcuoglu1, Tugba Gursoy, Fahri Ovalı, Ozge Serce, Guner Karatekin.   

Abstract

OBJECTIVE: Vancomycin-resistant Enterococcus (VRE) colonisation can be controlled with strict adherence to infection control measures. We describe a VRE outbreak coincident with bacterial probiotic trial. Relationship between probiotic and VRE colonisation, and other possible risk factors were investigated.
METHODS: Two hundred and ten infants with gestational age less than 32 weeks had been randomised for a trial with probiotic preparation containing Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium lactis, fructooligosaccharide, galactooligosaccharide, colostrums and lactoferrin (NBL probiotic ATP®; Nobel, Istanbul, Turkey) between February 2012 and August 2013 when a VRE outbreak also took place. The existence of a relationship between this probiotic preparation and VRE colonisation was investigated.
RESULTS: The begining and end of the outbreak were coincident with the beginning and end of the probiotic trial. Demographic and clinical features of neonates did not differ between VRE colonised (n = 94) and non-colonised infants (n = 116) except for vancomycin (p = 0.012) and probiotic (p < 0.001) use.
CONCLUSIONS: Probiotic and vancomycin exposure were significant risk factors for VRE colonisation. The acquisition and transfer of resistance genes of bacteria may be mediated by probiotics. Therefore, the safety of probiotics is a concern and should be investigated further.

Entities:  

Keywords:  Newborn; probiotics; vancomycin-resistant Enterococcus

Mesh:

Substances:

Year:  2014        PMID: 25163639     DOI: 10.3109/14767058.2014.958462

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  8 in total

1.  Assessment of some metabolic activities and potential probiotic properties of eight Enterococcus bacteria isolated from white cheese microbiota.

Authors:  Rasta Hajikhani; Derya Onal Darilmaz; Zehra Nur Yuksekdag; Yavuz Beyatli
Journal:  Antonie Van Leeuwenhoek       Date:  2021-06-04       Impact factor: 2.271

Review 2.  What is a host? Incorporating the microbiota into the damage-response framework.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2014-11-10       Impact factor: 3.441

3.  Probiotic supplementation and associated infant gut microbiome and health: a cautionary retrospective clinical comparison.

Authors:  C Quin; M Estaki; D M Vollman; J A Barnett; S K Gill; D L Gibson
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

4.  Synbiotics use for preventing sepsis and necrotizing enterocolitis in very low birth weight neonates: a randomized controlled trial.

Authors:  Ozge Serce Pehlevan; Derya Benzer; Tugba Gursoy; Guner Karatekin; Fahri Ovali
Journal:  Clin Exp Pediatr       Date:  2020-02-05

Review 5.  Probiotic Supplementation During the Perinatal and Infant Period: Effects on Gut Dysbiosis and Disease.

Authors:  Elisabet Navarro-Tapia; Giorgia Sebastiani; Sebastian Sailer; Laura Almeida Toledano; Mariona Serra-Delgado; Óscar García-Algar; Vicente Andreu-Fernández
Journal:  Nutrients       Date:  2020-07-27       Impact factor: 5.717

6.  Treatment with Saccharomyces boulardii and Escherichia coli Nissle is safe and associated with reduced nosocomial transmission of vanB vancomycin-resistant Enterococcus faecium on an early rehabilitation ward in Germany: a retrospective analysis.

Authors:  Stefan Borgmann; Beate Rieß; Rabea Siegmund; Guido Werner; Ingo Klare
Journal:  Ther Clin Risk Manag       Date:  2019-02-27       Impact factor: 2.423

7.  Determinants of the Very Low-Birth-Weight Infant's Intestinal Microbiome: A Systematic Review.

Authors:  Katelyn Desorcy-Scherer; Marion M Bendixen; Leslie A Parker
Journal:  J Perinat Neonatal Nurs       Date:  2020 Jul/Sep       Impact factor: 2.522

8.  Safety and acceptability of Lactobacillus reuteri DSM 17938 and Bifidobacterium longum subspecies infantis 35624 in Bangladeshi infants: a phase I randomized clinical trial.

Authors:  Yana Emmy Hoy-Schulz; Kaniz Jannat; Thomas Roberts; Saira Husain Zaidi; Leanne Unicomb; Stephen Luby; Julie Parsonnet
Journal:  BMC Complement Altern Med       Date:  2016-02-02       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.